JPMorgan raised the firm’s price target on Ascendis Pharma (ASND) to $200 from $168 and keeps an Overweight rating on the shares. The firm ...

Ascendis Pharma A/S (ASND) shares rallied 10.4% in the last trading session to close at $168.84. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a price target ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...

Assetmark Inc. raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 32.9% in the 4th quarter, ...

Ascendis Pharma A/S Price Performance NASDAQ:ASND opened at $138.18 on Tuesday. The stock has a market cap of $8.39 billion, a P/E ratio of -19.46 and a beta of 0.62. Ascendis Pharma A/S has a one ...

Ascendis Pharma A/S (Nasdaq: ASND) shared 52-week data from the open-label extension period of its ongoing Phase 3 PaTHway Trial... ByInvesting.com • Oct 16, 2023 Ascendis Pharma Presents ...

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual ...

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual ...

Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Wednesday, setting a price target of $178, which is approximately ...